Prognostic Value of Combined SATB۲ and Ki۶۷ Expression in Colorectal Cancer Patients: A Retrospective Cohort Study

Introduction: Colorectal cancer is the third most prevalent malignancy, with limited prognostic tools due to its heterogeneity. This study examined the simultaneous expression of SATB۲ and Ki۶۷ in colorectal cancer patients by immunohistochemistry, with progression-free survival (PFS) and patient demographics.Materials and Methods: The study employed an observational cohort design with a cross-sectional approach, defined as a retrospective-prospective clinicopathological analysis of ۱۲۸ colorectal cancer patients to examine SATB۲/Ki۶۷ immunoreactivity, including variables such as diagnosis duration, progression-free survival (PFS), age, sex, tumor location, grading, histopathological types, and TNM classification. Survival and ROC curve analysis tests were used to determine ۴۶ months as the PFS cutoff and survival criterion.Results: Fifty-six individuals survived PFS, while ۷۲ did not. Patients averaged ۵۴.۴۵ years old, with a ۲۲-۶۷ months PFS, averaging ۴۷ months. Colorectal tubular adenocarcinoma patients had the highest PFS; PFS was lower for rectal cancer patients. SATB۲ expression exhibited no significant changes based on gender or patient age; however, female patients showed increased Ki۶۷ expression compared to males. The average expressions of SATB۲ and Ki۶۷ were ۴۰.۲۱% ± ۲۹.۴۱% and ۲۵.۲۷% ± ۲۳.۱۶%, respectively. According to TNM staging, ۶۸.۹% of patients were categorized in stages I–II, ۲۳.۴% in stage III, and ۷.۸% in stage IV, with survival rates declining as tumor metastasis increased. Conclusions: The study suggested that evaluating SATB۲ expression during colorectal cancer treatment could clarify its prognostic importance. SATB۲ expression correlates positively with colorectal cancer survival; nevertheless, elevated Ki۶۷ levels negatively impact prognosis, particularly when SATB۲ levels are high.

کلیدواژه ها:

SATB۲ ، Ki۶۷ ، colorectal cancer ، Progression Free Survival ، immunohistochemistry